[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
..
Publication Charge
►Publication Fee
..
In Press
 In Press Articles
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 13, Issue 4 (Autumn 2022) ::
Caspian J Intern Med 2022, 13(4): 693-698 Back to browse issues page
Can we consider soluble herpes virus entry mediator (sHVEM) as a tumor marker?
Seyed Mohammad Javadzadeh , Mohsen Tehrani , Mohsen Keykhosravi , Rajehe Mohamadian-Amiri , Omolbanin Amjadi , Nasim Hafezi , Ehsan Zabouli , Mobina Montazeriun , Abolghasem Ajami
Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran , ajami36@gmail.com
Abstract:   (1662 Views)
Background: Immune checkpoint molecules have critical roles in directing immune responses into co-inhibitory and co-stimulatory signals. Herpes virus entry mediator (HVEM) is a receptor of tumor necrosis factor receptor superfamily with unique features due to its interaction with both inhibitory and stimulatory ligands. The aim of this study was to measure the serum level of the soluble form of HVEM in patients with gastric, colorectal and breast cancers and evaluating its diagnostic and prognostic value.
Methods: The concentration of the soluble HVEM (sHVEM) was determined in the serum of 36 patients with breast cancer, 50 patients with colorectal cancer and 59 patients with gastric cancer using ELISA method. Moreover, 50 healthy donors (HD) as well as 31 patients with non-ulcer dyspepsia (NUD) were used as control groups. The patients’ samples were obtained from the Biobank of Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Results: The level of sHVEM was significantly higher in patients with gastric (P=0.001) and breast cancer (P=0.01) than in control groups (HD). The higher level of sHVEM was observed in colorectal cancer patients in comparison with HD group, although it was not significant. Moreover, the elevated level of sHVEM was shown to be higher significantly in stage III and IV compared to stage I and II in breast cancer (P=0.03). Similar finding was detected in gastric and colorectal cancers, but not to be statistically significant.
Conclusion: The results of the present study suggest that the serum level of sHVEM may be considered as a promising indicator for diagnosis as well as evaluating the progression of cancers such as gastric, breast and colorectal cancers.

 
Keywords: Herpesvirus entry mediator, gastric cancer, breast cancer, colorectal cancer
Full-Text [PDF 265 kb]   (428 Downloads)    
Type of Study: Original Article | Subject: Oncology
Received: 2021/06/24 | Accepted: 2021/09/18 | Published: 2022/09/28
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Javadzadeh S M, Tehrani M, Keykhosravi M, Mohamadian-Amiri R, Amjadi O, Hafezi N, et al . Can we consider soluble herpes virus entry mediator (sHVEM) as a tumor marker?. Caspian J Intern Med 2022; 13 (4) :693-698
URL: http://caspjim.com/article-1-2978-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 4 (Autumn 2022) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.07 seconds with 40 queries by YEKTAWEB 4645